Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Sales | 4,284,281 | 4,130,550 | 4,171,022 | 4,024,655 | 4,234,387 |
| Cost of Goods | 714,850 | 597,900 | 614,436 | 626,209 | 675,985 |
| Gross Profit | 3,569,432 | 3,532,650 | 3,556,587 | 3,398,446 | 3,558,402 |
| Operating Expenses | 1,955,081 | 1,670,550 | 1,658,728 | 1,578,154 | 1,938,890 |
| Operating Income | 1,615,200 | 1,863,000 | 1,898,294 | 1,820,501 | 1,620,495 |
| Interest Expense | 36,252 | 17,400 | -1,823 | 56,054 | 119,184 |
| Other Income | -3,408 | -450 | 14,127 | 3,402 | 1,743 |
| Pre-tax Income | 1,575,540 | 1,845,150 | 1,914,244 | 1,767,849 | 1,503,054 |
| Income Tax | 322,869 | 374,700 | 400,105 | 369,454 | 299,425 |
| Net Income Continuous | 1,252,671 | 1,470,450 | 1,514,139 | 1,398,395 | 1,203,629 |
| Net Income | $1,252,671 | $1,470,450 | $1,514,139 | $1,398,395 | $1,203,629 |
| EPS Basic Total Ops | 0.25 | 0.29 | 0.30 | 0.28 | 0.24 |
| EPS Basic Continuous Ops | 0.25 | 0.29 | 0.30 | 0.27 | 0.24 |
| EPS Diluted Total Ops | 0.25 | 0.29 | 0.30 | 0.27 | 0.24 |
| EPS Diluted Continuous Ops | 0.25 | 0.29 | 0.30 | 0.27 | 0.24 |
| EBITDA(a) | $1,778,129 | $1,970,852 | $2,009,702 | $1,912,791 | $1,770,946 |